Skip to content

Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction

Strengthening the Case for Ongoing Reduction of Exposure to Traffic-Related Air Pollution

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02017431
Acronym
DE3
Enrollment
13
Registered
2013-12-20
Start date
2014-01-31
Completion date
2017-04-30
Last updated
2017-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergies

Keywords

Diesel exhaust, Particle depleted diesel exhaust, Air pollution, Airway responsiveness, Allergies

Brief summary

The study probes the effects of combined exposures to diesel exhaust and allergens on lung function and on the immune system, specifically focusing on the ability of a particle depletion technique to attenuate effects we and others have seen previously. Individuals are exposed to either filtered air (FA), carefully controlled levels of diesel exhaust (DE) or particle-depleted diesel exhaust (PDDE) in our exposure chamber, after which the investigators will administer an inhaled allergen challenge. 48h later, a procedure called bronchoscopy is used to collect samples from the lungs. After 1 month, the entire procedure is to be repeated with one of the alternate exposures. This will be repeated 4 times (4 exposures; 2 filtered air, 1 diesel exhaust, 1 particle-depleted diesel exhaust)

Detailed description

1. Purpose/Objective: The aim of this study is to investigate the ability of depletion of diesel exhaust particles to attenuate adverse effects of diesel exhaust on lung function and on allergic responses. 2. Hypotheses: Hypothesis 1: Allergen-specific immune response (specific IgG4, etc; relevant responses in DNA methylation and proteomics) in allergen-challenged airways in sensitized individuals is increased by diesel exhaust synergy. Hypothesis 2: Synergistic responses will be greater in asthmatics than in non-asthmatics. Hypotheses 3: Synergy is attributable to the particulate fraction of DE (i.e. is normalized by particle depletion). 3. Justification: Diesel exhaust consists of both gaseous and particulate air pollutants. In recent studies, cardiovascular effects seem attenuated when the particulate portion is removed. We would like to know if that is true for respiratory and immunological endpoints. Understanding these changes may help us prevent health problems associated with air pollution in the future. 4. Research Method: Blinded crossover experiment between four conditions (DE and allergen, PDDE and allergen, FA and allergen, FA and saline), randomized and counter-balanced to order. Each condition will be separated by a 4-week washout period. An inhaled allergen or saline challenge is delivered after each exposure (DE, PDDE, or FA). 24 h post challenge, airway reactivity will be assessed with a methacholine challenge. 48 h post challenge, bronchoalveolar lavage (BAL), airway brushes and tissue biopsies will be obtained for analysis of immune activation. Nasal lavage samples will also be collected to examine responses in the upper airways and blood and urine will be studied to examine systemic responses. Spirometry and methacholine challenge will be used to assess effects on airway function.

Interventions

Subject specific allergen is inhaled on day 1 of the triad

OTHERSaline

Saline is inhaled on day 1 of the triad

OTHERParticle depleted diesel exhaust

High-efficiency particulate filtration of diesel exhaust

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 19 and 49 years * Non-smoking * Positive skin prick test for at least one of: birch, grass, or dust

Exclusion criteria

* Using inhaled corticosteroids * Pregnant or planning to be pregnant in the next 12 months / Breastfeeding * Usage of bronchodilators more than three times per week. * Co-morbidities (as assessed by the primary investigator) * Taking part in other studies * Unwilling to withhold bronchodilator, aspirin, anti-coagulant, antihistamine or decongestant medications or caffeine prior to testing procedures. * FEV1(Forced expiratory volume in one second) \< 70% predicted. * Allergy to lidocaine, fentanyl, midazolam or salbutamol. * Unstable asthma (i.e exacerbation in 2 weeks preceding testing)

Design outcomes

Primary

MeasureTime frameDescription
Immune response to allergen +/- DE (BAL)48 hoursBAL cellular differential and activation,
Immune response to allergen +/- DE (Th1/Th2/IgE/IgG4)48 hoursTh1/Th2 profile and IgE and IgG4 specific to the allergen used for allergen challenge will be assessed.

Secondary

MeasureTime frameDescription
Epithelial cell DNA methylation48 hoursDetermine if allergen-induced changes in DNA methylation within epithelial cells is augmented by DE (300 µg/m3 inhaled for two hours) and attenuated by PDDE.
Proteomic signature48 hoursDetermine if allergen-induced changes in proteomic profile within epithelial cells is augmented by DE (300 µg/m3 inhaled for two hours) and attenuated by PDDE.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026